MA56074B1 - Anticorps contre le sars-cov-2 - Google Patents

Anticorps contre le sars-cov-2

Info

Publication number
MA56074B1
MA56074B1 MA56074A MA56074A MA56074B1 MA 56074 B1 MA56074 B1 MA 56074B1 MA 56074 A MA56074 A MA 56074A MA 56074 A MA56074 A MA 56074A MA 56074 B1 MA56074 B1 MA 56074B1
Authority
MA
Morocco
Prior art keywords
cov
antibodies against
formula
compound represented
against sars
Prior art date
Application number
MA56074A
Other languages
English (en)
Other versions
MA56074A (fr
Inventor
Davide Corti
Florian A Lempp
Amalio Telenti
Katja Fink
Martina Beltramello
Elisabetta Cameroni
Dora Pinto
Gyorgy Snell
Original Assignee
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vir Biotechnology Inc filed Critical Vir Biotechnology Inc
Publication of MA56074A publication Critical patent/MA56074A/fr
Publication of MA56074B1 publication Critical patent/MA56074B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C07K16/102—
    • C07K16/104—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne l'utilisation d'un composé représenté par la formule (i) ou de ses sels pharmaceutiquement acceptables dans la préparation de médicaments pour prévenir ou traiter les maladies infectieuses à coronavirus. Le composé représenté par la formule (i) est utilisé pour traiter les patients atteints d'une pneumonie causée par un nouveau coronavirus, et présente des avantages évidents en ce qui concerne le rapport de conversion négative du test d'acide nucléique viral, le cours de conversion négative et le temps de guérison et de sortie de l'hôpital.
MA56074A 2020-02-26 2021-02-25 Anticorps contre le sars-cov-2 MA56074B1 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US202062981984P 2020-02-26 2020-02-26
US202062982661P 2020-02-27 2020-02-27
US202062987298P 2020-03-09 2020-03-09
US202062989522P 2020-03-13 2020-03-13
US202062990369P 2020-03-16 2020-03-16
US202062992082P 2020-03-19 2020-03-19
US202062994235P 2020-03-24 2020-03-24
US202063001204P 2020-03-27 2020-03-27
US202063003214P 2020-03-31 2020-03-31
US202063005206P 2020-04-03 2020-04-03
US202063010589P 2020-04-15 2020-04-15
US202063011971P 2020-04-17 2020-04-17
US202063014024P 2020-04-22 2020-04-22
US202063023788P 2020-05-12 2020-05-12
US202063025133P 2020-05-14 2020-05-14
US202063039813P 2020-06-16 2020-06-16
US202063043653P 2020-06-24 2020-06-24
US202063050331P 2020-07-10 2020-07-10
US202063052810P 2020-07-16 2020-07-16

Publications (2)

Publication Number Publication Date
MA56074A MA56074A (fr) 2022-04-06
MA56074B1 true MA56074B1 (fr) 2023-11-30

Family

ID=74758682

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56074A MA56074B1 (fr) 2020-02-26 2021-02-25 Anticorps contre le sars-cov-2

Country Status (26)

Country Link
US (3) US11168128B2 (fr)
EP (2) EP3872091B1 (fr)
JP (2) JP7275405B2 (fr)
KR (1) KR20220164465A (fr)
AU (2) AU2021227687B2 (fr)
BR (1) BR112022017048A2 (fr)
CA (1) CA3158752C (fr)
CL (1) CL2022002335A1 (fr)
CO (1) CO2022013525A2 (fr)
DK (1) DK3872091T5 (fr)
ES (1) ES2954629T3 (fr)
FI (1) FI3872091T3 (fr)
HR (1) HRP20231031T1 (fr)
HU (1) HUE062777T2 (fr)
IL (1) IL295801A (fr)
LT (1) LT3872091T (fr)
MA (1) MA56074B1 (fr)
MX (1) MX2022010537A (fr)
PL (1) PL3872091T3 (fr)
PT (1) PT3872091T (fr)
RS (1) RS64645B1 (fr)
SG (1) SG11202110145SA (fr)
SI (1) SI3872091T1 (fr)
SM (1) SMT202300397T1 (fr)
TW (1) TWI859420B (fr)
WO (1) WO2021173753A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
CA3155725A1 (fr) * 2019-09-25 2021-04-01 Universitat Stuttgart Modules de liaison comprenant des domaines ehd2 modifies
UY39135A (es) * 2020-03-26 2021-10-29 Univ Vanderbilt ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
MY197648A (en) 2020-04-02 2023-06-30 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
CN116096412A (zh) 2020-04-10 2023-05-09 因维德公司 对冠状病毒s蛋白质具有特异性的化合物及其用途
PH12022500028A1 (en) 2020-06-03 2024-05-06 Regeneron Pharma Methods for treating or preventing sars-cov-2 infections and covid -19 with anti-sars-cov-2 spike glycoprotein antibodies
TW202207983A (zh) * 2020-06-12 2022-03-01 美商維爾生物科技股份有限公司 用於sars-cov-2感染的抗體療法
JP2023534922A (ja) 2020-07-06 2023-08-15 フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子
WO2022010921A1 (fr) * 2020-07-06 2022-01-13 Flagship Pioneering Innovations Vi, Llc Molécules de liaison à l'antigène ciblant le sars-cov-2
WO2022047033A1 (fr) 2020-08-26 2022-03-03 Flagship Pioneering Innovations Vi, Llc Molécules de liaison à l'antigène ciblant le sars-cov-2
WO2022054068A1 (fr) * 2020-09-14 2022-03-17 Ramot At Tel-Aviv University Ltd. Anticorps pour la prévention, le traitement et la détection d'une infection à coronavirus
EP4217739A4 (fr) * 2020-09-22 2024-03-13 Becton, Dickinson and Company Dosage à base de cellules pour la détection d'anticorps dans un échantillon
AU2021362007A1 (en) 2020-10-16 2023-06-22 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
US12109237B2 (en) * 2020-12-15 2024-10-08 Rutgers, The State University Of New Jersey S309 chimeric antigen receptors and methods of use
BR112024000744A2 (pt) 2021-07-14 2024-04-30 Regeneron Pharma Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno
WO2023001736A1 (fr) 2021-07-19 2023-01-26 Universität Für Bodenkultur Wien Anticorps igg3 anti-sars-cov-2 modifiés
WO2023034871A1 (fr) * 2021-09-01 2023-03-09 Vir Biotechnology, Inc. Thérapies par anticorps à haute concentration contre infection par sars-cov-2
US20240400652A1 (en) * 2021-09-01 2024-12-05 Vir Biotechnology, Inc. Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023039442A1 (fr) * 2021-09-08 2023-03-16 Vir Biotechnology, Inc. Polythérapies à base d'anticorps à large spectre de neutralisation pour infection par sars-cov-2
WO2023039540A2 (fr) * 2021-09-10 2023-03-16 Jacobs Technion-Cornell Institute Compositions et procédés pour déterminer des réponses immunitaires humorales contre des coronavirus saisonniers et prédire l'efficacité de ciblage de spicule du sars-cov-2, gravité de maladie covid-19, et pour permettre des interventions
US20240398911A1 (en) * 2021-09-15 2024-12-05 The Board Of The Trustees Of The University Of Illinois Engineered receptors and monoclonal antibodies for cronaviruses and uses thereof
WO2023046057A1 (fr) * 2021-09-24 2023-03-30 南京金斯瑞生物科技有限公司 Anticorps monoclonal dirigé contre le mutant l452r de protéine de spicule de sars-cov-2 et son utilisation
JP2024536381A (ja) * 2021-10-07 2024-10-04 セキラス ピーティーワイ リミテッド 抗ＳＡＲＳ－ＣｏＶ－２抗体及びその使用ＩＩ
WO2023086827A1 (fr) * 2021-11-09 2023-05-19 Rhode Island Hospital Prédiction d'anticorps contre la covid-19 parmi des survivants avec séquençage d'arn profond
EP4433613A1 (fr) 2021-11-15 2024-09-25 VIR Biotechnology, Inc. Substituts virologiques et moléculaires de réponse à l'anticorps neutralisant le sars-cov-2 sotrovimab
WO2023094980A1 (fr) * 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Anticorps contre le coronavirus
CN114107223B (zh) * 2021-11-25 2024-03-26 湖北省疾病预防控制中心（湖北省预防医学科学院） 利用TPCK胰酶提高SARS-CoV-2病毒细胞培养滴度的方法
WO2023122211A2 (fr) * 2021-12-21 2023-06-29 Duke University Anticorps du coronavirus et leurs utilisations
EP4460516A2 (fr) * 2022-01-03 2024-11-13 Twist Bioscience Corporation Anticorps bispécifiques du sars-cov-2 et procédés d'utilisation
JP2025504364A (ja) * 2022-01-08 2025-02-12 カロジェン コーポレイション 慢性ｂ型肝炎感染症を処置または防止するための複数抗原治療ワクチン
CN116444656B (zh) * 2022-01-10 2023-09-22 东莞市朋志生物科技有限公司 一种鉴别新冠突变型抗原的抗体、试剂及方法
TWI868567B (zh) * 2022-01-26 2025-01-01 中央研究院 冠狀病毒之特異性抗體及其用途
WO2023150307A2 (fr) * 2022-02-03 2023-08-10 Abpro Corporation Compositions et méthodes contre un virus
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
WO2023201256A1 (fr) * 2022-04-12 2023-10-19 Vir Biotechnology, Inc. Thérapies par anticorps à haute dose contre une infection par le sars-cov-2
EP4508077A1 (fr) 2022-04-14 2025-02-19 Invisishield Technologies Ltd. Compositions pour prévenir ou traiter des infections par la grippe
CA3256035A1 (fr) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions pour prévenir ou traiter des infections à coronavirus
US11993644B2 (en) 2022-05-06 2024-05-28 Generate Biomedicines, Inc. Antigen binding molecules targeting SARS-CoV-2
US20230365658A1 (en) * 2022-05-16 2023-11-16 Lawrence Livermore National Security, Llc REPAIRED THERAPEUTIC AND PROPHYLACTIC ANTIBODIES AGAINST SARS-CoV-2 VARIANTS
KR20240008997A (ko) * 2022-07-12 2024-01-22 (재) 스크립스코리아항체연구원 사스-코로나 바이러스 2 중화 항체
WO2024058987A2 (fr) * 2022-09-14 2024-03-21 Merck Sharp & Dohme Llc Polypeptides efficaces contre de multiples coronavirus
EP4615579A1 (fr) 2022-11-13 2025-09-17 Generate Biomedicines, Inc. Molécules de liaison à l'antigène ciblant sars-cov-2
WO2024112818A1 (fr) * 2022-11-22 2024-05-30 Humabs Biomed Sa Anticorps anti-sars-cov-2 modifiés et leurs utilisations

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2004024750A2 (fr) 2002-09-13 2004-03-25 Dyax Corporation Ligands liant cd44
EP1597280B2 (fr) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Production d'anticorps monoclonaux par transformation de lymphocytes b par le virus d'epstein barr
JP2007528700A (ja) 2003-04-08 2007-10-18 コロノヴァティブ ビー．ブイ． Ｓａｒｓ
EP1644414B1 (fr) 2003-07-22 2015-01-14 Crucell Holland B.V. Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci
WO2005012360A2 (fr) 2003-07-22 2005-02-10 Crucell Holland B.V. Molecules de liaison dirigees contre le coronavirus du syndrome respiratoire aigu severe et applications de celles-ci
US7396914B2 (en) 2003-08-04 2008-07-08 University Of Massachusetts SARS nucleic acids, proteins, antibodies, and uses thereof
JP4620591B2 (ja) 2003-09-24 2011-01-26 協和発酵キリン株式会社 ヒトインスリン様成長因子に対する遺伝子組換え抗体
US7750123B2 (en) 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
US7553944B2 (en) 2004-07-21 2009-06-30 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
EP1812067B1 (fr) 2004-11-11 2012-03-21 Crucell Holland B.V. Compositions contre le coronavirus du sras et utilisations de ces compositions
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2035454A2 (fr) 2006-05-19 2009-03-18 Amgen, Inc. Anticorps au coronavirus sras
CN101522717A (zh) 2006-08-04 2009-09-02 阿斯利康(瑞典)有限公司 针对ErbB2的人抗体
WO2008042814A2 (fr) 2006-09-29 2008-04-10 California Institute Of Technology Récepteurs mart-1 des lymphocytes t
BRPI0808673A2 (pt) 2007-03-06 2014-08-12 Symphogen A/S Anticorpos recombinantes para tratamento de infecções com vírus sinciciais respiratórios.
EP2242768A4 (fr) 2008-01-17 2012-03-14 Humabs Llc Anticorps monoclonaux humains à neutralisation croisée dirigés contre sars-cov et procédés d'utilisation de ces derniers
WO2009097133A2 (fr) 2008-01-30 2009-08-06 Monsanto Technology, Llc Plantes transgéniques présentant des caractéristiques agronomiques améliorées
EA034783B1 (ru) 2009-03-20 2020-03-20 Эмджен Инк. Антитело-антагонист, специфичное для гетеродимера альфа4бета7
CA2780221A1 (fr) 2009-11-04 2011-05-12 Fabrus Llc Procedes pour l'optimisation d'anticorps basee sur la maturation d'affinite
RS60033B1 (sr) 2009-11-24 2020-04-30 Medimmune Ltd Ciljano vezujući agensi usmereni na b7-h1
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
KR101299753B1 (ko) 2010-11-19 2013-08-23 주식회사 단바이오텍 소 코로나바이러스 항원 결정기를 포함하는 스파이크 재조합 단백질 및 이에 대한 항체
SG11201406762QA (en) 2012-01-20 2014-11-27 Genzyme Corp Anti-cxcr3 antibodies
AR090244A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
CN104379734B (zh) 2012-05-18 2018-05-15 诺维信公司 具有改进的转化效率的细菌突变体
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
MX2016008667A (es) 2013-12-30 2017-02-02 Epimab Biotherapeutics Inc Inmunoglobulina con fab en tandem y usos de esta.
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016073906A2 (fr) 2014-11-06 2016-05-12 Scholar Rock, Inc. Immunoessais liés à des facteurs de croissance transformants
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
TN2017000432A1 (en) 2015-04-10 2019-04-12 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
JP2018516879A (ja) 2015-05-08 2018-06-28 ユーリカ セラピューティックス， インコーポレイテッド Ｈｐｖ１６−ｅ７ペプチド／ｍｈｃ複合体を標的化する構築物およびその使用
EP3294774B1 (fr) 2015-05-13 2024-08-28 Zumutor Biologics, Inc. Protéines afucosylées, cellule exprimant cette protéine et methodes associées
JP7628764B2 (ja) 2015-09-29 2025-02-12 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
EP3426688A1 (fr) 2016-03-08 2019-01-16 Innate Pharma Anticorps neutralisant les siglecs
BR112018076281A2 (pt) 2016-06-20 2019-03-26 Kymab Limited imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
US10759855B2 (en) 2016-12-02 2020-09-01 Rigel Pharmaceuticals, Inc. Antigen binding molecules to TIGIT
AU2017375646A1 (en) 2016-12-16 2019-05-30 Merck Patent Gmbh Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
EA202090149A1 (ru) 2017-06-28 2020-05-31 Ридженерон Фармасьютикалз, Инк. Антигенсвязывающие белки против вируса папилломы человека (hpv) и способы их применения
WO2019024979A1 (fr) 2017-07-31 2019-02-07 Institute For Research In Biomedicine Anticorps à domaines fonctionnels dans la région de coude
US11390686B2 (en) 2017-08-09 2022-07-19 University Of Saskatchewan HER3 binding agents and uses thereof
KR101895228B1 (ko) 2017-08-23 2018-10-30 대한민국 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도
BR112020005676A2 (pt) 2017-09-22 2020-10-20 WuXi Biologics Ireland Limited novos complexos polipeptídicos biespecíficos
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
MY197648A (en) 2020-04-02 2023-06-30 Regeneron Pharma Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021203053A1 (fr) * 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunothérapie ciblant une région conservée dans des coronavirus sras
US20240059757A1 (en) * 2020-04-14 2024-02-22 Vir Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
JP2023525039A (ja) * 2020-05-08 2023-06-14 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体
WO2021247925A1 (fr) * 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Immunothérapie guidée par une structure dirigée contre le sars-cov-2
TW202207983A (zh) * 2020-06-12 2022-03-01 美商維爾生物科技股份有限公司 用於sars-cov-2感染的抗體療法
CN112062859B (zh) * 2020-07-24 2022-08-09 沣潮医药科技（上海）有限公司 用于病原体清除的嵌合抗原受体及其应用

Also Published As

Publication number Publication date
US11479599B2 (en) 2022-10-25
SMT202300397T1 (it) 2024-01-10
IL295801A (en) 2022-10-01
CA3158752A1 (fr) 2021-09-02
US11168128B2 (en) 2021-11-09
AU2021227687B2 (en) 2023-02-23
CA3158752C (fr) 2023-08-08
WO2021173753A1 (fr) 2021-09-02
EP4245373A3 (fr) 2023-12-20
PT3872091T (pt) 2023-09-19
EP3872091A1 (fr) 2021-09-01
KR20220164465A (ko) 2022-12-13
FI3872091T3 (fi) 2023-08-31
US20210371504A1 (en) 2021-12-02
US20230331821A1 (en) 2023-10-19
AU2023203201A1 (en) 2023-06-15
US20210261650A1 (en) 2021-08-26
LT3872091T (lt) 2023-10-10
JP7275405B2 (ja) 2023-05-17
CO2022013525A2 (es) 2022-12-20
ES2954629T3 (es) 2023-11-23
MX2022010537A (es) 2022-09-21
JP2023009046A (ja) 2023-01-19
MA56074A (fr) 2022-04-06
SI3872091T1 (sl) 2023-12-29
TW202146442A (zh) 2021-12-16
SG11202110145SA (en) 2021-10-28
PL3872091T3 (pl) 2023-12-27
RS64645B1 (sr) 2023-10-31
EP3872091B1 (fr) 2023-06-14
AU2021227687A1 (en) 2022-10-20
TWI859420B (zh) 2024-10-21
DK3872091T5 (da) 2024-08-12
EP4245373A2 (fr) 2023-09-20
HUE062777T2 (hu) 2023-12-28
HRP20231031T1 (hr) 2023-12-22
BR112022017048A2 (pt) 2022-11-16
CL2022002335A1 (es) 2023-07-21
JP2023505613A (ja) 2023-02-09
DK3872091T3 (da) 2023-09-11

Similar Documents

Publication Publication Date Title
MA56074B1 (fr) Anticorps contre le sars-cov-2
MA57574A1 (fr) Utilisation d'un composé nucléoside dans le traitement des maladies infectieuses à coronavirus
Zhou et al. Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation
Staples Jr et al. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival
Avidan et al. Low complication rate associated with cesarean section under spinal anesthesia for HIV-1–infected women on antiretroviral therapy
MA27348A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
RU2007119390A (ru) Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с
ATE464292T1 (de) Pharmazeutisch aktive sulfonamid-derivate
NO20054264L (no) Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer
AR034312A1 (es) Composicion de vacuna que comprende al menos un antigeno del virus de la inmunodeficiencia humana (vih), kit de vacunacion que la comprende, uso de un antigeno de vph y vhs para la preparacion de la composicion de vacuna y procedimiento para la preparacion de dicha vacuna
WO2020114444A1 (fr) Utilisation de diacéréine dans la préparation de médicaments antiviraux et traitement d'infections virales
WO2021164689A1 (fr) Application de nelfinavir dans la préparation d'un médicament pour la prévention et le traitement d'une nouvelle pneumonie à coronavirus
ATE92928T1 (de) Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen.
Davis et al. Inhibition of the human immunodeficiency virus-1 protease and human immunodeficiency virus-1 replication by bathocuproine disulfonic acid CU1+
US5519028A (en) Antiviral preparations
CN113648313A (zh) 一种哌嗪取代-2-甲基苄腈类化合物zk-22在制备抗冠状病毒药物中的应用
Böttiger et al. Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3′-fluorothymidine
SE7600801L (sv) Forfarande for framstellning av 4-(4-bifenylyl)-butanoler
EP1374867A1 (fr) Utilisation de la chloroquine, de l'hydroxychloroquine et de dérivés de la 4-aminoquinoline comme médicament dans des thérapies anti-rétrovirales, actives contre des souches VIH et contre des souches VIH résistantes, qui sont résistantes aux inhibiteurs nucléosidiques et non-nucléosidiques de la transcriptase inverse et aux inhibiteurs de protéases
US20050059745A1 (en) Antiviral therapy
KR900701278A (ko) 바이러스 감염 치료용 담즙산
McCullough et al. Human immunodeficiency virus infection: a review of the mode of infection, pathogenesis, disease course, and the general and clinical manifestations
CA2028758A1 (fr) Utilisation d'une benzodiazepine et d'un derive de la phenylpyrrylcetone
NO20051833L (no) 4-(3,5-dicyanofenoksy)pyrazolderivater for anvendelse som transkriptasemodulatorer ved behandling av IA HIV.
Armbruster HIV-1 infection: recent developments in treatment and current management strategies